RESUMEN
We have previously shown that a transplantable murine tumor (CE mammary carcinoma) causes marked neutrophilia and excessive bone resorption in vivo. In order to understand the humoral mechanism of these tumor-induced phenomena, we successfully established a cell line (CE 816) and subsequently cloned CE mammary carcinoma cells in serum-free culture conditions. Cultured CE tumor cells continued to induce neutrophilia and hypercalcemia when they were transplanted back into mice. Conditioned medium (CM) prepared from the CE 816 cell line and control non-neutrophilia-inducing tumor cells were evaluated for stimulation of neutrophilic colony formation, embryonic bone cell proliferation, and bone resorption in vitro assays. Both the CE 816 and control tumor CM demonstrated colony-stimulating activity, but the CE 816 CM stimulated more neutrophilic colonies than the control tumor at all experimental conditions examined. The CE 816 CM demonstrated bone-resorbing activity but not control tumor CM. Both types of CM stimulated proliferation of embryonic bone cells. Production of colony-stimulating and bone-mitogenic activities was directly related to the tumor cell growth in vitro. CM prepared from four clones of CE tumor cells demonstrated both colony-stimulating and bone cell-mitogenic activities. These studies provided evidence that CE mammary carcinoma cells produce factors affecting granulopoiesis and bone cells in vitro, and these activities are clonal in origin.
Asunto(s)
Resorción Ósea/efectos de los fármacos , Sustancias de Crecimiento/metabolismo , Hipercalcemia/etiología , Leucocitosis/etiología , Neoplasias Mamarias Experimentales/metabolismo , Animales , Células Cultivadas , Células Clonales/metabolismo , Ensayo de Unidades Formadoras de Colonias , Factores Estimulantes de Colonias/metabolismo , Femenino , Masculino , Neoplasias Mamarias Experimentales/complicaciones , Ratones , Ratones Endogámicos , Trasplante de Neoplasias , Neutrófilos/efectos de los fármacosRESUMEN
We prepared aqueous extracts of whole femorae and tibiae of embryonic chicks. An amount of extract containing 25 microgram of protein resulted in a 500% increase in DNA synthesis in calvarial cell culture, and significant effects were detected with 5 microgram (55%). The time course for stimulation of DNA synthesis showed a peak occurring 16-20 h after addition of the extract. This matrix factor is nondialyzable, and fractionation on a column of Sephadex G-100 indicated a molecular weight of 60-80,000. At the maximum dose used, [3H]proline incorporation into total protein of calvarial cells was increased by 55%, and thus far, all fractions active in promoting DNA synthesis have been found to increase collagen synthesis in cultured chick tibiae. These data are consistent with an effect on osteoblasts as well as bone precursor cells. Extracts prepared from tibiae of 2-day-old chicks, from which the marrow had been removed, also stimulated DNA synthesis (280% increase), thus ruling out the possibility that the factor is a relatively nonspecific nitrogen from the hematopoietic cell line. We conclude that bone matrix contains a substance which could regulate bone formation in vitro by control of mitosis in osteogenic precursors and/or stimulation of osteoblast activity.
Asunto(s)
Huesos/fisiología , Extractos de Tejidos/farmacología , Animales , Médula Ósea/fisiología , División Celular/efectos de los fármacos , Embrión de Pollo , Replicación del ADN/efectos de los fármacos , Cinética , Técnicas de Cultivo de Órganos , Prolina/metabolismo , Biosíntesis de ProteínasRESUMEN
Cells obtained from male quail kidneys by digestion with collagenase and hyaluronidase were plated and maintained in a chemically defined, serum-free medium. Culture dishes (35 mm) were inoculated with 1.5 . 10(6) cells which became confluent in 5 days. The cells maintained an epithelial-like morphology over the entire culture period. During a 2 h incubation the cells metabolized 25--30% of the 10 nM 25-hydroxyvitamin D-3 (25-OH-D-3) provided. Seven metabolites were chromatographically separated on Sephadex LH-20. Three have been identified as 1 alpha, 25-dihydroxyvitamin D-3 (1,25(OH)2D-3), 24,25-dihydroxyvitamin D-3 (24,25(OH)2D-3) and 1 alpha, 24,25-trihhydroxyvitamin D-3 (1,24,25(OH)3D-3). The activities of the 25-OH-D-3:1 alpha- and 24-hydroxylases increased eight times faster than the cell number in 5 days. Preincubation of the cells with 10 nM 25-OH-D-3 or 1,25(OH)2D-3 decreased 1,25(OH)2D-3 synthesis, and increased both 24,25(OH)2D-3 and metabolite IV synthesis. The decrease in 25-OH-D-3:1 alpha-hydroxylase activity required a 2 h preincubation with 25-OH-D-3, while stimulation of 25-OH-D-3:24-hydroxylase activity and metabolite IV production required a 6 h preincubation. Incubations of cells for 1 h with parathyroid hormone resulted in a 30-fold increase in cyclic AMP in the medium. A 6 h preincubation with parathyroid hormone decreased 24,25(OH)2D-3) synthesis 50% relative to control cells. These results demonstrate the amenability of this system for studying the regulation of 25-OH-D-3 metabolism, as well as its use for other in vitro studies on renal cell function in a chemically defined culture system.
Asunto(s)
Riñón/metabolismo , Vitamina D/metabolismo , Animales , Células Cultivadas , Coturnix , AMP Cíclico/metabolismo , Hidroxicolecalciferoles/metabolismo , Hidroxilación , Riñón/citología , Masculino , Hormona Paratiroidea/farmacologíaRESUMEN
The presence of gap junctions between osteoblastic cells has been previously reported. For this study we used the rat osteosarcoma cell line UMR 106, which expresses the osteoblastic phenotype, as a model to characterize further the nature, physiology, and regulation of gap junctions. Northern blot analysis identified a 3.0-kilobase RNA species corresponding to the gap junction protein connexin 43. The presence of two other connexin RNA species (26 and 32) could not be detected by this method in these cells. The identified connexin RNA was amplified by reverse transcription coupled to polymerase chain reaction; the sequence of the amplified product appears identical to the sequence of a cloned rat heart connexin 43 gene. After treatment with PTH, forskolin, and 8-Br-cAMP (a cAMP analog), the levels of connexin 43 RNA in UMR 106 cells increased. Further evidence for the role of PTH and cAMP in the physiology of gap junctions in these cells was obtained with Lucifer yellow dye transfer experiments. Gap-junctional intercellular communication increased in response to PTH and forskolin (an inducer of adenylate cyclase activity). Expression of connexin 43 RNA increased severalfold in response to PTH in a concentration- and time-dependent fashion. Connexin 43 RNA and its PTH-mediated stimulation were also observed in several other osteoblastic cell lines. The roles of PTH and forskolin in regulating the physiological state of gap junctions were confirmed in primary cultures of rat calvaria osteoblasts.
Asunto(s)
Comunicación Celular/efectos de los fármacos , Proteínas de la Membrana/biosíntesis , Proteínas de Neoplasias/biosíntesis , Osteoblastos/efectos de los fármacos , Hormona Paratiroidea/farmacología , 8-Bromo Monofosfato de Adenosina Cíclica/farmacología , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Neoplasias Óseas/patología , Huesos/química , Colforsina/farmacología , Conexinas , AMP Cíclico/farmacología , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Proteínas de la Membrana/genética , Datos de Secuencia Molecular , Miocardio/química , Proteínas de Neoplasias/genética , Osteoblastos/metabolismo , Osteosarcoma/patología , Ratas , Cráneo/citología , Células Tumorales CultivadasRESUMEN
A hypothesis has been advanced that parenteral solutions as commonly formulated for use in clinical practice have a toxic effect on cell metabolism. A specific component of these solutions, sodium acetate, has been suggested to disrupt normal bone turnover and therefore to contribute to the osteopenia observed in patients receiving hemodialysis and parenteral nutrition (PN). We developed an in vitro model to test the hypothesis that sodium acetate at concentrations that are infused in PN solutions has a deleterious effect on bone metabolism. Osteoblasts and preosteoblasts from 16- to 17-day-old embryonic chick calvaria, and tibiae and femora from 10-day-old embryonic chicks were grown in BGJb medium (control) or in BGJb medium plus sodium acetate (5, 10, or 20 mM). Calvarial cell proliferation was quantified by direct cell counts as well as by incorporation of [3H]TdR into DNA as an index of cell proliferation. Calvarial cell alkaline phosphatase activity was quantified by the ability of extracts of the cultured cells to hydrolyze p-nitrophenyl phosphate to p-nitrophenol, and bone growth was determined by measuring final dry weight. Calvarial cell counts as well as DNA synthesis showed a dose-dependent decrease in the presence of sodium acetate (5-20 mM) compared with controls. [3H]TdR incorporation was decreased a mean 19% with 5 mM, 38% with 10 mM, and 63% with 20 mM acetate. Alkaline phosphatase activity per cell increased 48% with 5 mM, 140% with 10 mM, and 355% with 20 mM acetate. Cell viability as assessed by trypan blue exclusion was identical for test and control media (greater than 95%).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Acetatos/farmacología , Desarrollo Óseo/efectos de los fármacos , Huesos/efectos de los fármacos , Ácido Acético , Fosfatasa Alcalina/metabolismo , Animales , Fenómenos Fisiológicos Sanguíneos , Huesos/citología , Recuento de Células , División Celular/efectos de los fármacos , Células Cultivadas , Pollos , Concentración de Iones de Hidrógeno , Técnicas de Cultivo de Órganos , Tamaño de los Órganos/efectos de los fármacos , Osteoblastos/efectos de los fármacosRESUMEN
Accumulating evidence indicates that gap junctions, primarily composed of connexin 43 (Cx43), are distributed extensively throughout bone. We have previously reported that in osteoblastic cells parathyroid hormone (PTH) increases both the steady-state levels of transcripts for Cx43 and gap-junctional intercellular communication in a process involving cyclic adenosine monophosphate (cAMP). We now present data showing that the mechanism of stimulation of Cx43 gene expression by PTH involves an increased rate of Cx43 gene transcription without affecting Cx43 transcript stability in UMR 106 osteoblastic cells. Activation of the protein kinase C pathway is not involved in this process. Inhibiting translation consistently decreases the PTH-mediated stimulation of Cx43 gene expression at all the times we tested (1-3 h). However, this effect is only partial, demonstrating that de novo protein synthesis is required for full stimulation. PTH increases the steady-state levels of Cx43 mRNA in several osteoblastic cell lines, albeit to different levels. We were unable to detect PTH stimulation in ROS 17/2.8 osteoblastic cells, suggesting that the effect of PTH on Cx43 gene expression may depend on the developmental state of the cell along the osteoblastic differentiation pathway. In the MC3T3-E1 preosteoblastic cell line, we find that PTH increases Cx43 gene expression in proliferating and maturing osteoblastic cells, but not in nondividing, differentiated osteoblasts, where the basal level of Cx43 gene expression is elevated. Unlike PTH, the osteotropic hormones 1,25-dihydroxyvitamin D3 and 17beta-estradiol do not appear to affect Cx43 gene expression in UMR 106 osteoblastic cells.
Asunto(s)
Conexina 43/efectos de los fármacos , Conexina 43/genética , Osteoblastos/efectos de los fármacos , Osteoblastos/metabolismo , Hormona Paratiroidea/farmacología , Células 3T3 , Animales , Calcitriol/farmacología , Carcinógenos/farmacología , Estrógenos/farmacología , Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica , Genes/efectos de los fármacos , Genes/genética , Ratones , Osteoblastos/citología , Osteosarcoma , Fenotipo , Proteínas/efectos de los fármacos , Proteínas/genética , Proteínas/metabolismo , ARN/efectos de los fármacos , ARN/metabolismo , Ratas , Acetato de Tetradecanoilforbol/farmacología , Transcripción Genética/efectos de los fármacos , Transcripción Genética/genética , Células Tumorales CultivadasRESUMEN
We have investigated signaling (cAMP) and anabolic responses (mineralization of extracellular matrix [ECM]) to parathyroid hormone (PTH) in long-term (30 days) cultures of MC3T3-E1 cells, a murine model of osteoblast differentiation. Expression of PTH/PTH-related peptide receptor (PTH1R) mRNA is detected early and remains relatively constant for 2 weeks with somewhat higher levels observed during the second half of the culture period. In contrast to the relatively stable PTH1R mRNA expression, the cAMP response to PTH varies markedly with no response at day 5 and a marked response (80-fold versus control) by day 10. Responsiveness to PTH remains elevated with fluctuations of 30- to 80-fold stimulation throughout the remainder of the culture period. The timing and duration of PTH treatment to achieve in vitro mineralization of ECM was evaluated. When continuous PTH treatment was initiated before day 20, mineralization decreased. If continuous PTH treatment began on or after day 20, mineralization was unaffected. However, if treatment began on day 20 and then stopped on day 25, mineralization on day 30 was increased 5-fold. This mineralization response to intermittent PTH was confirmed in primary cultures of murine and human osteoblastic cells. These data provide a potential basis for understanding the differential responses to PTH (anabolic versus catabolic) and indicate the developmental temporal variance of anabolic and catabolic responses. Since cAMP signaling was relatively unchanged during this interval (day 10-30) and stimulation of adenylate cyclase only partially mimicked the PTH effect on increased mineralization, other signaling pathways are likely to be involved in order to determine the specific anabolic response to short-term PTH treatment during the differentiation process.
Asunto(s)
Osteoblastos/metabolismo , Hormona Paratiroidea/farmacología , Fosfatasa Alcalina/metabolismo , Animales , División Celular/efectos de los fármacos , Células Cultivadas , Colforsina/farmacología , AMP Cíclico/metabolismo , Matriz Extracelular/efectos de los fármacos , Matriz Extracelular/metabolismo , Humanos , Ratones , Minerales/metabolismo , Osteoblastos/efectos de los fármacos , ARN Mensajero/metabolismo , Receptores de Hormona Paratiroidea/genética , Receptores de Hormona Paratiroidea/metabolismo , Factores de TiempoRESUMEN
Mesenchymal stem cells (MSCs) residing in bone marrow (BM) are the progenitors for osteoblasts and for several other cell types. In humans, the age-related decrease in bone mass could reflect decreased osteoblasts secondary to an age-related loss of osteoprogenitors. To test this hypothesis, BM cells were isolated from vertebral bodies of thoracic and lumbar spine (T1-L5) from 41 donors (16 women and 25 men) of various ages (3-70 years old) after death from traumatic injury. Primary cultures were grown in alpha modified essential medium with fetal bovine serum for 13 days until adherent cells formed colonies (CFU-Fs). Colonies that stained positive for alkaline phosphatase activity (CFU-F/ALP+) were considered to have osteogenic potential. BM nucleated cells were plated (0.5, 1, 2.5, 5, or 10 x 106 cells/10-cm dish) and grown in dexamethasone (Dex), which promotes osteoblastic differentiation. The optimal plating efficiency using BM-derived cells from donors of various ages was 5 x 106 cells/10-cm dish. BM-derived cells were also grown in the absence of Dex at this plating density. At the optimal plating density, in the presence of Dex, the number of CFU-F/ALP+ present in the BM of the younger donors (3-36 years old) was 66.2 +/- 9.6 per 106 cells (mean +/- SEM), but only 14.7 +/- 2.6 per 106 cells in the older donors (41-70 years old). With longer-term culture (4-5 weeks) of these BM cells in medium containing 10 mM beta-glycerophosphate and 100 microg/ml ascorbic acid, the extracellular matrix mineralized, a result consistent with mature osteoblastic function. These results demonstrate that the number of MSCs with osteogenic potential (CFU-F/ALP+) decreases early during aging in humans and may be responsible for the age-related reduction in osteoblast number. Our results are particularly important in that the vertebrae are a site of high turnover osteoporosis and, possibly, the earliest site of bone loss in age-related osteoporosis.
Asunto(s)
Células de la Médula Ósea/citología , Mesodermo/citología , Osteogénesis/fisiología , Células Madre/citología , Células del Estroma/citología , Adolescente , Adulto , Factores de Edad , Anciano , Fosfatasa Alcalina/metabolismo , Células de la Médula Ósea/enzimología , Recuento de Células , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Niño , Preescolar , Ensayo de Unidades Formadoras de Colonias , Dexametasona/farmacología , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Peptidylglycine alpha-amidating monooxygenase is hormonally, developmentally, and nutritionally regulated. In several tissues concomitant changes in enzyme activity and the level of expression of a known amidated peptide have been demonstrated. We report that neonatal mouse calvarium, a rapidly mineralizing bone, has detectable amidation enzyme activity. The level of activity varied 3-10-fold during the first 9 d of life. Production of one or more amidated peptides by bone may be coordinately regulated.
Asunto(s)
Desarrollo Óseo , Huesos/enzimología , Oxigenasas de Función Mixta , Complejos Multienzimáticos , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/metabolismo , Envejecimiento , Animales , Animales Recién Nacidos , Cinética , RatonesRESUMEN
In certain neurons, alternative RNA processing generates calcitonin gene-related peptide (CGRP) from the same gene that encodes the hormone calcitonin. As CGRP-containing nerve fibers are prominent in skeleton, we evaluated the effects of CGRP on osteoblasts. Because the vasodilatory effect of neural CGRP in smooth muscle probably involves inhibition of unstimulated Ca2+ uptake, we examined the acute effects of CGRP on this parameter in rat osteoblastic cells. CGRP inhibits 45Ca2+ uptake in both UMR 106 osteosarcoma and RCOB-3 osteoblastic cells. This inhibition is rapid (0.5 min), occurs with an EC50 of 1 nM, and cannot be demonstrated in the presence of 0.1 mM diltiazem, a blocker of voltage-dependent Ca2+ channels. Depolarization of bone cells with high extracellular potassium (K+) also blocks the effect of CGRP on 45Ca2+ uptake, suggesting a central role for K+ channels in mediating this action. In agreement with this hypothesis, the effect of CGRP is blocked by 1 microM glybenclamide, a specific inhibitor of ATP-sensitive potassium (K(ATP)) channels, or by pretreatment of cells with 1 mM iodoacetic acid to deplete intracellular ATP. Blocking Ca2+-activated potassium channels with 1 mM tetraethylammonium does not prevent CGRP's effect. Pinacidil, a specific activator of K(ATP) channels, mimics CGRP's effect. Both CGRP and pinacidil also produce a small significant stimulation of cellular Ca2+ efflux in UMR 106 cells. These data suggest that inhibition of diltiazem-sensitive Ca2+ channels occurs secondary to the hyperpolarization engendered by CGRP activation of K(ATP) channels in osteoblastic cells, an effect similar to that of CGRP on smooth muscle cells.
Asunto(s)
Adenosina Trifosfato/metabolismo , Péptido Relacionado con Gen de Calcitonina/metabolismo , Calcio/metabolismo , Osteoblastos/metabolismo , Canales de Potasio/metabolismo , Animales , Péptido Relacionado con Gen de Calcitonina/farmacología , Línea Celular , Relación Dosis-Respuesta a Droga , Activación del Canal Iónico/efectos de los fármacos , Transporte Iónico/efectos de los fármacos , RatasRESUMEN
Calcitonin gene-related peptide (CGRP) receptor component protein (RCP) is a novel protein that modulates CGRP responsiveness in a variety of cell types. Using probes based on the isolation of CGRP-RCP complementary DNA (cDNA) from a guinea pig organ of Corti cDNA library, we cloned human (h) and mouse (m) CGRP-RCP cDNAs, both of which encode 148-residue proteins that at the amino acid levels are approximately 88% identical to each other and to the 146-residue guinea pig CGRP-RCP. Northern blot analysis confirmed the presence of CGRP-RCP messenger RNA in all of the human and mouse tissues tested. In these human tissues, hCGRP-RCP messenger RNA (major band at approximately 3.1 kb, minor band at approximately 7.5 kb) was most prevalent in the testis. In the mouse, the highest abundance of CGRP-RCP RNA was clearly in the testis (major band at approximately 1.6 kb, minor band at approximately 1.1 kb). Based on this tissue distribution of RNA, we sought to identify the cells in the murine testis that contained CGRP-RCP protein. Numerous antisera generated against hCGRP-RCP, including one to recombinant hCGRP-RCP, exhibited strong immunoreactivity localized to the head region of spermatozoa. No CGRP-RCP immunoreactivity was observed in other cells at less mature stages of sperm maturation, in Sertoli or interstitial (Leydig) cells, or in human spermatozoa. Murine epididymal (mature) spermatozoa exhibited CGRP-RCP immunoreactivity identical to that of testicular spermatozoa. Spermatozoa that underwent an experimentally induced acrosome reaction (acrosomal discharge) lost their CGRP-RCP immunoreactivity. Therefore, it appears that CGRP-RCP is associated with the acrosome, suggesting that it may play an important role in reproduction.
Asunto(s)
ADN Complementario/biosíntesis , Receptores de Péptido Relacionado con el Gen de Calcitonina/genética , Testículo/metabolismo , Acrosoma/metabolismo , Secuencia de Aminoácidos , Animales , Epidídimo/metabolismo , Cobayas , Humanos , Masculino , Ratones , Datos de Secuencia Molecular , Proteínas Recombinantes/biosíntesis , Homología de Secuencia de AminoácidoRESUMEN
Cells isolated from embryonic chick intestine in culture convert 25-hydroxyvitamin-D3 to a number of more polar metabolites. Two of these metabolites have been identified with chemical and chromatographic methods as 24,25-dihydroxyvitamin-D3 (24,25(OH)2D3) and 1,25-dihydroxyvitamin-D3 (1,25(OH)2D3). The enzymes conform to substrate saturation kinetics. The apparent Km for substrate for the synthesis of 1,25(OH)2D3 and 24,25(OH)2D3 is 70 nM and 29 nM, respectively.
Asunto(s)
Calcitriol/biosíntesis , Dihidroxicolecalciferoles/biosíntesis , Intestinos/embriología , 24,25-Dihidroxivitamina D 3 , Animales , Células Cultivadas , Embrión de Pollo , Cromatografía Líquida de Alta Presión , Mucosa Intestinal/metabolismo , CinéticaRESUMEN
Expression of MET, the receptor for hepatocyte growth factor (HGF), has been associated with androgen-insensitive prostate cancer. In this study we evaluated MET activation by HGF and HGF action in prostate cancer cell lines. HGF causes phosphorylation (activation) of the MET receptor in three androgen-unresponsive cell lines (DU 145, PC-3, and ALVA-31) together with morphological change. Although HGF is known to stimulate the growth of normal epithelial cells, including those from prostate, we found that HGF inhibited ALVA-31 and DU 145 (hormone-refractory) cell lines. Moreover, HGF and vitamin D additively inhibited growth in each androgen-unresponsive cell line, with the greatest growth inhibition in ALVA-31 cells. Further studies in ALVA-31 cells revealed distinct cooperative actions of HGF and vitamin D. In contrast to the accumulation of cells in G1 seen during vitamin D inhibition of androgen-responsive cells (LNCaP), growth inhibition of the androgen-unresponsive ALVA-31 cell line with the HGF and vitamin D combination decreased, rather than increased, the fraction of cells in G1, with a corresponding increase in the later cell cycle phases. This cell cycle redistribution suggests that in androgen-unresponsive prostate cancer cells, HGF and vitamin D act together to slow cell cycle progression via control at sites beyond the G1/S checkpoint, the major regulatory locus of growth control in androgen-sensitive prostate cells.
Asunto(s)
Andrógenos/fisiología , Factor de Crecimiento de Hepatocito/farmacología , Neoplasias de la Próstata/patología , Vitamina D/farmacología , Ciclo Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Resistencia a Medicamentos , Sinergismo Farmacológico , Humanos , Masculino , Fosforilación , Neoplasias de la Próstata/metabolismo , Proteínas Proto-Oncogénicas c-met/genética , Proteínas Proto-Oncogénicas c-met/metabolismo , ARN Mensajero/metabolismo , Células Tumorales Cultivadas , Tirosina/metabolismo , Vitamina D/análogos & derivadosRESUMEN
Calcitonin gene-related peptide (CGRP) was examined for its effects on intracellular free Ca2+ concentration ([Ca2+]i) in UMR 106 osteoblast-like cells. Cells loaded with the Ca2+ dye FURA-2 dose-dependently responded to CGRP (1-100 nM) with transient two-fold increases in [Ca2+]i. An intracellular source for this Ca2+ transient was suggested by the failure of membrane depolarization with high extracellular K+ or acute depletion of extracellular Ca2+ ([Ca2+]e) with EGTA to attenuate this response. After cells were incubated for 45 min with 0.1 mM extracellular Ca2+ to deplete intracellular Ca2+ stores, CGRP produced a 25-30% decrease in [Ca2+]i rather than a transient increase. This calcium decrease was mimicked by membrane depolarization or by pinacidil, a specific activator of adenosine triphosphate (ATP)-sensitive potassium (KATP) channels, and blocked by glybenclamide, a specific blocker of KATP channels. Our data suggest that CGRP has diverse Ca2+ regulatory effects in UMR 106 cells, mobilizing Ca2+ from intracellular stores via classical signaling while possibly promoting cellular Ca2+ efflux or inhibiting uptake through voltage-dependent Ca2+ channels via KATP-mediated hyperpolarization.
Asunto(s)
Péptido Relacionado con Gen de Calcitonina/farmacología , Calcio/metabolismo , Osteoblastos/efectos de los fármacos , Adenosina Trifosfato/farmacología , Animales , Neoplasias Óseas/patología , Calcitonina/farmacología , Colforsina/farmacología , Relación Dosis-Respuesta a Droga , Ácido Egtácico/farmacología , Fura-2/química , Gliburida/farmacología , Guanidinas/farmacología , Osteoblastos/citología , Osteoblastos/metabolismo , Osteosarcoma/patología , Pinacidilo , Potasio/farmacología , Canales de Potasio/efectos de los fármacos , Ratas , Espectrometría de Fluorescencia , Células Tumorales Cultivadas , Vasodilatadores/farmacologíaRESUMEN
The in vivo action of insulin-like growth factor-I on bone metabolism has been studied using a new model. Insulin-like growth factor-I (IGF-I) was continuously infused into the arterial supply of the right hindlimb of ambulatory rats for up to 14 days and the effects on cortical and trabecular bone formation and the number of osteoclasts were determined by histomorphometric techniques. The contralateral limb acted as an internal control. IGF-I infusion significantly increased cortical bone formation (p less than 0.01). Trabecular bone was increased 22% (p = 0.07), but the infusion was only for seven days. These effects of IGF-I were age dependent, being absent in young, rapidly growing animals, but present at least until one year of age. IGF-I appears to be a purely anabolic hormone for bone formation, since it significantly stimulates osteoblasts and decreases the number of osteoclasts. Thus, although IGF-I mediates the growth-promoting effect of growth hormone, it does not mediate growth hormone's action on bone resorption.
Asunto(s)
Desarrollo Óseo/efectos de los fármacos , Resorción Ósea/metabolismo , Factor I del Crecimiento Similar a la Insulina/farmacología , Animales , Densidad Ósea/efectos de los fármacos , Recuento de Células/efectos de los fármacos , Femenino , Miembro Posterior , Infusiones Intraarteriales , Osteoblastos/efectos de los fármacos , Osteoclastos/efectos de los fármacos , Ratas , Ratas EndogámicasRESUMEN
To evaluate the potential of an animal model as a means to identify bone-targeted estrogens, we have studied the response of the skeleton of ovariectomized mice to prolonged estrogen treatment. Seventy female Swiss-Webster mice were randomly divided into ten groups, with nine groups undergoing bilateral ovariectomy and one group a sham procedure. Mice were injected subcutaneously once per week for nine weeks with one of the following doses of estrogen (17 beta-E2) in oil vehicle: 19.3, 38.5, 75, 150, 300, 500, 1000, or 3000 micrograms. One group of ovariectomized (OVX) mice and the sham operated animals received vehicle injections only. At the end of the nine-week experimental protocol, there were no significant differences in body weights among any treatment groups. However, when compared to control values, spleen weights in vehicle-treated OVX mice and in mice treated with 1000 micrograms or 3000 micrograms of 17 beta-E2 were significantly elevated (p less than .01). Liver weights in the OVX mice treated with 1000 or 3000 micrograms 17 beta-E2 were also increased significantly (p less than .05). Comparisons of uterine weights and cortical bone areas were strongly correlated with 17 beta-E2 dose (r2 = .86 and .94, respectively), with maximal increases observed at estradiol doses in excess of 500 micrograms per week. Furthermore, based on bone histomorphometry of in vivo fluorochrome labels, increases in cortical bone area could be attributed to accelerated rates of endosteal mineral apposition and bone formation. These results indicate that the comparison of the response of endosteal bone and uterine tissue in the OVX mice to chronic estrogen treatment offers the potential to identify estrogen and/or estrogen-like compounds with bone-specific activity.
Asunto(s)
Desarrollo Óseo/efectos de los fármacos , Estradiol/farmacología , Terapia de Reemplazo de Estrógeno , Ovario/fisiología , Animales , Peso Corporal/efectos de los fármacos , Huesos/patología , Modelos Animales de Enfermedad , Femenino , Ratones , Tamaño de los Órganos/efectos de los fármacos , Especificidad de Órganos/fisiología , OvariectomíaRESUMEN
Osteoblastic cells in long-term culture undergo a phenotypic maturation process leading to extracellular matrix (ECM) production and bone nodule (BN) formation. Cell-to-cell communication via gap junctions (GJC) can be detected between osteoblastic cells within 24 h of plating. We evaluated, in long-term cultures of osteoblastic cells, the effect of inhibiting GJC on the phenotypic maturation process and the expression of specific genes associated with this process. MC3T3-E1 cells were plated, and, after 24 h (day 0), cells were exposed to 18-alpha-glycyrrhetinic acid (AGA), a nontoxic reversible inhibitor of GJC. GJC, alkaline phosphatase (AP) activity, BN formation, and the relative level of transcripts encoding osteocalcin (OC), bone sialoprotein (bSP), osteopontin (OP), collagen alpha1 type I (alpha1ICol), and elongation factor-1a (EF1a) were evaluated on day 0 and every 4-7 days thereafter through day 30. GJC was assessed by fluorescent dye transfer. Gene expression was analyzed by northern blot and semiquantitative reverse transcription-polymerase chain reaction. GJC was detectable at day 0 and increased with time in culture. AGA (100 micromol/L) strongly inhibited GJC at all timepoints tested. Moreover, AGA-exposed cells showed a dose-dependent decrease in AP activity and a delay in the appearance of BN. This delayed phenotypic expression coincided with an inhibitory effect on the expression of the osteoblast-specific genes OC and bSP. Expression of alpha1ICol mRNA was also affected, but to a lesser extent, whereas OP and EF1a were not affected. Similar results were obtained with oleamide, an additional reversible inhibitor of GJC. In contrast, cells exposed to either vehicle or 100 micromol/L glycyrrhizic acid (a noninhibitory glycoside of 18-beta-glycyrrhetinic acid) were indistinguishable from untreated cells for all parameters evaluated. We conclude that GJC inhibition interferes with the maturation process of osteoblastic cells in culture, possibly by affecting signals regulating the expression of genes involved in the maturation/differentiation of the osteoblastic phenotype.
Asunto(s)
Comunicación Celular , Uniones Comunicantes/fisiología , Osteoblastos/citología , Células 3T3 , Fosfatasa Alcalina/metabolismo , Animales , Secuencia de Bases , Comunicación Celular/efectos de los fármacos , Cartilla de ADN , Uniones Comunicantes/efectos de los fármacos , Ácido Glicirretínico/farmacología , Ratones , Osteoblastos/efectos de los fármacos , Osteoblastos/enzimología , Osteoblastos/metabolismo , Fenotipo , Reacción en Cadena de la Polimerasa de Transcriptasa InversaRESUMEN
Previously we showed that physiological levels of parathyroid hormone (PTH) can increase the mineralization of extracellular matrix (ECM) by osteoblast-like cells in vitro. In this study, we assess the role of gap-junctional intercellular communication (GJC) in the PTH-enhanced mineralization of ECM in MC3T3-E1 cells, a murine culture model of osteoblastic differentiation. Messenger RNA and protein for connexin 43 (Cx43), the major component of MC3T3-E1 gap junctions, and GJC increased as the cells progressed toward a mature phenotype. Immunocytochemistry showed accumulation of Cx43 at the area of close contact between cells. The timing of the PTH treatment that increased matrix mineralization in these cells coincided with the highest expression of Cx43 and GJC. Administration of 18-alpha-glycyrrhetinic acid (AGA) promptly blocked GJC in cultures of MC3T3-E1 cells in a dose-dependent and reversible manner at all times tested during the culture period. Treatment with AGA, but not with an inactive analog, reversed the PTH-induced ECM mineralization. These data suggest that GJC mediates anabolic actions of PTH related to osteoblast-mediated mineralization.
Asunto(s)
Calcificación Fisiológica/efectos de los fármacos , Comunicación Celular/fisiología , Uniones Comunicantes/fisiología , Osteoblastos/metabolismo , Hormona Paratiroidea/farmacología , Animales , Comunicación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Células Cultivadas , Conexina 43/metabolismo , Ratones , Osteoblastos/citología , Osteoblastos/efectos de los fármacosRESUMEN
Bone formation and remodeling require continuous generation of osteoprogenitor cells from bone marrow stromal cells (MSC), which generate and respond to a variety of growth factors with putative roles in hematopoiesis and mesenchymal differentiation. In this study we examine the interaction of two such factors on the maturation of skeletal components. We previously reported that these factors, hepatocyte growth factor (HGF) and 1,25-dihydroxyvitamin D(3) (vitD(3)), act together to increase alkaline phosphatase in chondroblasts. We now describe the cooperative effect of these agents on MSC isolated and cultured from human vertebral bone marrow. MSC (passages 3-9) isolated from bone marrow cells of human vertebrae (T1-L5) from 22-36-year-old normal donors were first expanded in vitro and then plated in the presence or absence of 10 ng/mL HGF and/or 10 nmol/L vitD(3), for 7-18 days. HGF treatment increased cell proliferation 2.5-fold, with no effect on alkaline phosphatase activity. Whereas vitD(3) treatment inhibited cell growth by 50%, alkaline phosphatase activity was stimulated eightfold, although no mineralization was observed. HGF together with vitD(3) increased cell proliferation 1.5-fold and alkaline phosphatase activity 13-fold over untreated control. Moreover, mineralization was detected only with this combination. Our findings provide evidence that HGF in concert with vitamin D may promote growth and differentiation of human MSC into osteogenic cells.
Asunto(s)
Células de la Médula Ósea/efectos de los fármacos , Colecalciferol/farmacología , Factor de Crecimiento de Hepatocito/farmacología , Osteoblastos/efectos de los fármacos , Adulto , Fosfatasa Alcalina/metabolismo , Células de la Médula Ósea/citología , Células de la Médula Ósea/enzimología , Recuento de Células/métodos , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Células Cultivadas , Femenino , Humanos , Masculino , Osteoblastos/citología , Osteoblastos/enzimología , Columna Vertebral/citología , Columna Vertebral/efectos de los fármacos , Columna Vertebral/enzimología , Células del Estroma/citología , Células del Estroma/efectos de los fármacos , Células del Estroma/enzimologíaRESUMEN
Androgen excess and deficiency affect skeletal maturation and bone cell function. Understanding the molecular basis for these androgen effects could improve therapy/prevention of short stature and osteoporosis. Androgens act through binding to androgen receptors (ARs), which modulate gene transcription via interactions with DNA response elements on target genes. Because osteoblasts contain ARs at levels just below certain androgen-sensitive tissues, we sought to define the function of AR in a number of commonly used osteoblastic cell lines. Presence and quantification of AR protein and mRNA were evaluated by ligand binding assay, western blotting, and RNAse protection assay. AR-containing osteoblastic cell lines were exposed to nonaromatizable androgens and effects on gene expression were assessed. We found no evidence for direct effects of androgen on endogenous genes nor was androgen involved in modulation of parathyroid hormone effects on early gene activation. Androgen-sensitive reporter gene constructs were stimulated by androgen only when AR cDNA expression vectors were introduced into cells by cotransfection. We conclude that, in commonly used osteoblastic cell lines, the presence of AR at the levels described here does not guarantee androgen transcriptional activity. The effects of androgen on bone in vivo may involve direct stimulation of osteoblastic cells in a different setting or stage of differentiation. Alternatively, androgen may act on bone cells other than osteoblasts, or through metabolic conversion to estrogens.